Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021 by Sales of Branded, Generic, and Off-Label Drugs - Research and Markets

Research and Markets
Posted on: 30 Aug 17

The "Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021" report has been added to Research and Markets' offering.

The global graft vs host disease (GVHD) treatment market to grow at a CAGR of 7.15% during the period 2017-2021.

Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report also includes a discussion of the Key vendors operating in this market. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

According to the report, one driver in the market is increased prevalence of cancer. Globally, cancer is one of the life-threating diseases. As per National Institutes of Health (NIH), it is the second largest cause of death globally.

One trend in the market is inorganic growth strategies. The inorganic growth strategies are expected to contribute the growth of GVHD treatment market as the market is completely based on off-label usage. These inorganic growth strategies include global merger and acquisition, partnerships and regional acquisition.

Key vendors

  • Bristol-Myers Squibb
  • Novartis
  • Pfizer
  • F. Hoffmann-La Roche

Other prominent vendors

  • Abbott
  • AbbVie
  • Allergan
  • Anterogen
  • Astellas Pharma
  • Athersys
  • Baxter
  • Caladrius
  • Cellular Biomedicine Group
  • Cipla
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • Incyte Corporation
  • IPCA Laboratories
  • Kadmon Holdings
  • Lupin
  • Osiris Therapeutics
  • RedHill
  • Sanofi
  • Shire
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
  • ViaCyte

Key Topics Covered:

  1. Executive Summary
  2. Scope Of The Report
  3. Research Methodology
  4. Introduction
  5. Disease Overview
  6. Market Overview
  7. Pipeline Landscape
  8. Market Segmentation By Disease Type
  9. Geographical Segmentation
  10. Decision Framework
  11. Drivers And Challenges
  12. Market Trends
  13. Vendor Landscape
  14. Key Vendor Analysis
  15. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/mwfdxc/global_graft_vs

View source version on businesswire.com: http://www.businesswire.com/news/home/20170830005589/en/

Business Wire
www.businesswire.com

Last updated on: 30/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.